Neuroendocrine Key Regulator Gene Expression in Merkel Cell Carcinoma

Abstract

Merkel cell carcinoma (MCC) is a highly aggressive non-melanoma skin cancer of the elderly which is associated with the Merkel cell polyomavirus (MCPyV). MCC reveals a trilinear differentiation characterized by neuroendocrine, epithelial and pre/pro B-cell lymphocytic gene expression disguising the cellular origin of MCC. Here we investigated the expression of the neuroendocrine key regulators RE1 silencing transcription factor (REST), neurogenic differentiation 1 (NeuroD1) and the Achaete-scute homolog 1 (ASCL1) in MCC. All MCCs were devoid of REST and were positive for NeuroD1 expression. Only one MCC tissue revealed focal ASCL1 expression. This was confirmed in MCPyV-positive MCC cell lines. Of interest, MCPyV-negative cell lines did express REST. The introduction of REST expression in REST-negative, MCPyV-positive MCC cells downregulated the neuroendocrine gene expression. The lack of the neuroendocrine master regulator ASCL1 in almost all tested MCCs points to an important role of the absence of the negative regulator REST towards the MCC neuroendocrine phenotype. This is underlined by the expression of the REST-regulated microRNAs miR-9/9* in REST-negative MCC cell lines. These data might provide the basis for the understanding of neuroendocrine gene expression profile which is expected to help to elucidate the cellular origin of MCC.

Neoplasia (2018) 20, 1227–1235

Introduction

Merkel cell carcinoma (MCC) is a highly malignant non-melanoma skin cancer which predominantly arises in the sun-exposed skin of elderly patients [1,2]. Next to UV exposure and age, MCC are associated with immune deficiencies and the presence of clonally integrated Merkel cell polyomavirus (MCPyV) [3,4]. More than 80% of MCC are associated with MCPyV, and it has been shown that tumor cell proliferation of MCC is dependent on the expression of the oncogenic viral T antigens [5–7].

Although MCC accounts only for a minority of all cutaneous malignancies its incidence has increased worldwide and has tripled in the US and doubled in some European countries [8].
The 5-year survival of local MCC is 71% but only 20% in the presence of distant metastases [2]. Recent data of clinical trials on the use of immune checkpoint inhibitors in the treatment of patients with MCC stage IIIB/IV are promising [9,10].

Despite the major progress that has been made during the past years concerning the understanding of the etiopathogenesis and treatment, the cellular origin of MCC remains enigmatic [11]. It has been postulated that MCC either originates from Merkel cells or epidermal/dermal stem cells [11,12]. To date it is generally accepted that the post-mitotic Merkel cells do not constitute the cellular origin of MCC. Based on the frequently reported co-expression of PAX-5, TdT and immunoglobulins in MCCs, we have recently formulated the hypothesis that MCC originate from early B-cells, i.e. pre/pro B-cells [13,14].

The repressor element 1 (RE1) silencing transcription factor (REST) is a master repressor of neuronal gene expression and neuronal programs in non-neuronal lineages [15,16]. REST binds together with CoREST to the REST-binding site of neuronal genes, which leads to the inhibition of the expression of these genes [17]. In the absence of REST, neuronal genes will be expressed. Among other genes, REST negatively controls the neuronal target genes encoding chromogranin A and synaptophysin [18,19]. Although the absence of REST is insufficient to explain the full extent of chromogranin A expression, synaptophysin gene expression is predominantly regulated by REST [19]. REST has been proven to function as an oncogene in neural cells and as a tumor suppressor in non-neural cells [16]. In neoplastic neural cells, REST expression is switched on and is overexpressed, e.g. in medulloblastoma and in glioblastoma multiforme [20,21]. In contrast, in non-neural tumors REST acts as a tumor suppressor, revealing deletions of the REST locus on chromosome 4 in a significant proportion of tumors [22].

REST expression is negatively reciprocal regulated by the neuronal development regulator microRNA-9 (miR-9) during neural differentiation [23,24]. Further, its passenger strand miR-9* is downregulating CoREST: Recently it has been shown that miR-9 is upregulated in MCC [25]. Interestingly, it has been shown that miR-9 is activated by the human papillomavirus (HPV) E6 protein in cervical cancer [26]. In addition, REST has been shown to interact with other human DNA viruses, e.g. Herpes simplex virus and adenovirus [27–29].

The basic helix–loop–helix (BHLH) Achaete-scute homolog 1 (ASCL1) transcription factor is known as another master regulator of neuroendocrine differentiation and is detected in most neuroendocrine tumors as small cell lung cancer (SCLC) [30]. In addition, the transcription factor neurogenic differentiation 1 (NeuroD1) was considered as an alternative regulator of neuroendocrine differentiation.

In the present study, we assessed the expression of REST, NeuroD1 and ASCL1 in MCC and MCC cell lines. Moreover, the possible regulation of REST expression by promoter methylation was assessed with 5-aza-2′ deoxycytidine (5-aza-2′-dC) treatment and a methylation specific PCR of the REST promoter CpG islands. In addition, we tested the expression of miR-9/9* in REST-positive and REST-negative MCC cell lines in relation to MCPyV in order to understand in as much the regulation of neuroendocrine gene expression in MCC is affected by MCPyV.

Materials and Methods

Patient Samples
Twenty-eight formalin-fixed and paraffin-embedded (FFPE) primary and metastatic MCC tissues were obtained from the archives of the Department of Pathology, Maastricht University Medical Center + (Table 1). All use of tissue and patient data was in agreement with the Dutch Code of Conduct for Observational Research with Personal Data (2004) and Tissue (2001, "www.federa.org/sites/default/files/digital_version_first_part_code_in_uk_2011_12092012.pdf"). MCCs were previously diagnosed by histology and immunohistochemistry for CK20, CD56, synaptophysin and chromogranin A in routine diagnostic and have been reviewed by 2 experienced pathologists (VW, AZH).

Cell Lines
The MCPyV-positive MCC cell lines MKL-1, MKL-2, WaGa, PeTa, BroLi, MS-1 the MCPyV-negative MCC cell lines MCC13, MCC26 and the B-ALL cell line REH were used. All MCC cell lines were kindly provided by Jürgen Becker (University Hospital Essen, Essen, Germany). REH was obtained from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Germany.

The cell lines were cultured in Gibco® RPMI 1640 medium with 10% fetal calf serum (FCS) (Gibco®, ThermoFisher SCIENTIFIC, The Netherlands) in an incubator at 37°C and 5% CO2.

Immunohistochemistry
The expression of REST, ASCL1 and NeuroD1 was tested by immunohistochemistry (IHC) in 20 primary and 8 metastatic MCCs, in the MCPyV-positive MCC cell lines MKL-1, MKL-2, WaGa and in the MCPyV-negative MCC cell lines MCC13 and MCC26. In addition, the expression of these genes was assessed in the B-cell acute...
lymphoblastic leukemia (B-ALL) cell line REH. The following antibodies and dilutions were used in this study: Anti-MCPyV LT-antigen (clone: CM2B4) dilution 1:100, SANTA CRUZ BIOTECHNOLOGY, Germany; anti-REST (clone: CL0381) dilution 1:100, Sigma Aldrich, the Netherlands; anti-MASH1/Achaete-scute homologel (clone: 24B72D11.1) dilution 1:100, Abcam, UK; NeuroD1 (clone: 3H8) dilution 1:100, Abnova, Germany; anti-Cytokeratin 20 (clone: Ks 20.8) “ready to use antibody”, Dako, the Netherlands. All IHC stainings were performed on a Dako Autostainer 48 Link using the EnVision FLEX Visualization Kit K8008 Dako as described previously and according to standard diagnostic routine protocols and manufacturer instructions [31]. The IHC double staining procedure of REST and Cytokeratin 20 (CK20) was performed manually by using the Dako Kit K8008 for anti-REST and K5005 for the staining of anti-CK20. The double staining method was adapted to the standard routine protocol.

**REST-GFP Transfection**
The cell line WaGa was transfected with human cDNA ORF GFP tagged clone NM_005612 from Origene. The expression vector led to a transient expression of REST-GFP. The transfection was performed by using Lipofectamine 3000 (ThermoFisher SCIENTIFIC, The Netherlands) according to the instructions of the manufacturer. The expression level changes of synaptophysin and chromogranin A were assessed by immunofluorescence microscopy by using a standard protocol. The cells were formalin fixed, permeabilized with 0.3% Triton X-100, blocked with 5% BSA, incubated with the first antibodies against chromogranin A 1:250 (SP11, ThermoFisher SCIENTIFIC, The Netherlands) or anti-synaptophysin 1:250 (SP12, ThermoFisher SCIENTIFIC, The Netherlands), stained with the second antibody anti Rabbit Texas Red conjugated (T-2767, ThermoFisher SCIENTIFIC, The Netherlands) or anti-MASH1/Achaete-scute homologel (SP11, ThermoFisher SCIENTIFIC, The Netherlands) or anti-Rest Tagged clone NM_005612 from Origene. The expression vector led to a transient expression of REST-GFP. The transfection was performed by using Lipofectamine 3000 (ThermoFisher SCIENTIFIC, The Netherlands) according to the manufacturers’ instructions. All experiments were repeated at least 3 times.

**Treatment of Cell Lines with 5-Aza-2’ Deoxycytidine**
The cell lines MKL-1, MKL-2, MCC13 and MCC26 were treated with 0.5 μM, 1.0 μM and 2.0 μM of 5-aza-2’-dc (Sigma-Aldrich, the Netherlands) which was added every 24 hrs. In total, the cells were exposed to the demethylation agent for 96 h. After exposure the cells were formalin fixed and REST expression was tested by IHC.

**Methylation Specific PCR (MSP)**
The genomic DNA of all cell lines was extracted using the “NucleoSpin” Tissue kit (Macherey-Nagel, Germany). The location of the CpG islands was previously described by Kreisler et al. [32] and was reproduced using the CpG island searcher [32,33]. The gDNA was bisulfite converted using the EpiTect Bisulfite Kit (Qiagen, the Netherlands) according to the manufacturers’ instruction. CpG islands were amplified using specific primers for both methylated and unmethylated specific primer (Table S2). As positive control, the unmethylated and the methylated Epitect Control DNAs (Qiagen, the Netherlands) were used.

**Statistics**
The significance of the qRT-PCR data was determined with Graphpad Prism 6 by using the One-Way ANOVA. Data were expressed as the mean ± standard deviation (SD). P-values of <0.05 were considered as statistically significant.

**Results**

**Protein Expression of REST, ASCL1 and NeuroD1 in MCC**
Of the 28 MCC tissues, 23 (82.1%) were MCPyV-positive and 5 (17.8%) MCPyV-negative as tested by IHC. All MCCs (Table 1) were completely devoid of REST expression as assessed by IHC.
Double staining for CK20- and REST-expression of MCC tissues revealed a specific nuclear expression of REST within the tumor infiltrating lymphocytes but not in the MCC cells expressing CK20 (Figure 1B). All MCCs were negative for ASCL1, except one case which revealed focal expression for ASCL1 (ID8, Table 1). All MCCs revealed a specific moderate to strong nuclear expression of NeuroD1 (Table 1, Figure 1D).

In addition, REST expression was assessed in MCC cell lines by IHC. MCPyV-positive cell lines (MKL-1, MKL-2, WaGa, PcTa, BroLi, MS-1) were negative for REST expression (Figure 2 and Supplemental Table S1). In contrast, the MCPyV-negative cell lines (MCC13, MCC26, REH) revealed a specific nuclear REST expression. In compliance with the MCC specimens, all cell lines were negative for ASCL1 expression, but revealed a strong and...
specific nuclear NeuroD1 expression in all cell lines. All MCPyV-positive cell lines showed a uniform expression pattern for the tested transcription factors. Therefore, for further experiments MKL-1, MKL-2 and WaGa cells were used.

**REST Transcript Gene Expression in MCC Cell Lines**

The presence of REST transcripts was assessed in MKL-1, MKL-2, WaGa, MCC13, MCC26 and REH cells (Figure 3). No relevant REST transcripts were detected in MCPyV-positive MCC cell lines MKL-1, WaGa and MKL-2. Exon 1 (R1), exon 3 (R3) and intron-exon spanning amplification of exon 1 and exon3 (REST) MKL-1, MKL-2 and WaGa were not detectable using cDNA (A) but by using genomic DNA (B) level. The MCPyV-negative cell lines were positive for REST cDNA. The expression of REST, chromogranin A, synaptophysin and miR-9/9* were analyzed by means of a RT-qPCR. The cq values were normalized to MKL-1 and the sd of n = 2 is shown. Only for the REST expression the cq values were normalized to MCC13. The REST RT-qPCR confirmed this result and shows a comparable REST transcript level in MCC13, MCC26 and REH (C). For chromogranin A and synaptophysin is the pattern vice versa. Whereas WaGa showed a 10-fold higher chromogranin A expression compared to the other MCPyV-positive cell lines (D). For The miR-9 and miR-9* expression the REST positive cell lines MCC13, MCC26 and REH showed an 94 to 76% respectively lower expression of miR-9 and miR-9* compared to the MCPyV-positive cell lines MKL-1, MKL-2 and WaGa. The p-value for the assessed genes was <0.5.

![Figure 3. Analysis of REST, synaptophysin, chromogranin A and miR-9/9* expression.](image)

The sequencing of the cDNA amplification products for MCC13, MCC26 and REH showed the expression of the identical REST isoform (variant 1) in these three cell lines. The cDNA REST amplification product of MKL-2 (Figure 3A; Supplemental Figure
S1) showed a faint PCR product, which was confirmed as REST by sequencing, carrying an insertion of 67-bp. This insertion had previously been reported in SCLC and is supposed to result in a truncated REST \[34,35\].

**Chromogranin A, Synaptophysin and miR-9/miR-9* Expression in MCC**

The detected patterns of chromogranin A and synaptophysin expression levels in MCPyV-positive cell lines revealed an inverse correlation with REST expression (Figure 3D). Of interest, a 10-fold higher transcript expression level of chromogranin A was observed in WaGa cells compared to MKL-1 and MKL-2. Interestingly, the WaGa cells revealed an approximately 3-fold higher expression level of the MCPyV T antigens compared to MKL-1 and MKL-2 (Figure 3D and Supplemental Figure S2). MiR-9 expression in MCC cell lines was assessed in REST-negative, MCPyV-positive MCC cell lines MKL-1, MKL-2 and WaGa, and REST-positive, MCPyV-negative MCC cell lines MCC13 and MCC26 by means of qRT-PCR. The expression of miR-9 and miR-9* was normalized to MKL-1 (Figure 3E).

The REST-negative, MCPyV-positive, cell lines showed a high miR-9/miR-9* expression compared to the REST-positive, MCPyV-negative, MCC cell lines and the B-ALL cell line REH.

**Effects of the Transient Expression of REST-GFP in WaGa Cells Assessed by IF**

In order to determine the functional importance of REST expression in MCPyV-positive MCC cell lines, WaGa cells were transfected with a GFP-tagged REST and its transient expression was detected in the nuclei. The REST-GFP positive WaGa cells were stained for chromogranin A and synaptophysin. A significant decrease of chromogranin A and synaptophysin compared to the not transfected WaGa cells was observed (Figures 4 and S3) in the transfected cells compared to the non-transfected cells.

**Methylation of the REST Promoter in MCCs**

REST expression had been shown to be regulated by methylation of promoter CpG islands \[32\]. Since neither REST protein or transcript expression could be detected in the MCPyV-positive cell lines, MKL-1, MKL-2, MCC13, MCC26 and REH were treated with 5-aza-2′-dC (Figure 5A). Of interest, after 0.5 and 1.0 μM treatment with 5-aza-2′-dC MCC26 showed exclusively the response of approximate 50 to 60% respectively decrease of REST expression. However, due to the high standard deviation this failed to reach statistical significance. The expression of REST was not altered in the MCPyV-positive cell lines MKL-1 and MKL-2 by 5-aza2′-dC treatment as assessed by IHC and RT-PCR (Figure 5B). The REST expression in the other cell lines was not significantly altered by the 5-aza2′dC treatment.

A methylation specific PCR was performed on the CpG islands 1 and 3 (Figure 5D) of the genomic DNA of the above-mentioned cell lines and no methylation was detected on both CpG islands in all tested cell lines.

**Discussion**

In the present study we investigated the expression of key regulator genes of neuroendocrine gene expression in MCC. For this purpose a
A large number of MCC tissues including MCC cell lines was tested for the expression of REST, ASCL1, and NeuroD1. REST acts as a repressor of neuroendocrine gene expression, whereby loss of REST expression leads to the expression of synaptophysin and chromogranin A. In contrast, ASCL1 and NeuroD1, both proneural basic-helix-loop-helix proteins, have both been identified as activators of neuroendocrine lineage genes expression [36]. In contrast, ASCL1 induces synaptophysin expression and NeuroD1 activates CD56 (NCAM1) expression [37,38].

All MCC tissues and cell lines in this study were negative for ASCL1 expression except one MCC which revealed a focal expression of ASCL1 (Table 1). Ralston and colleagues (2008) have previously reported that MCCs were all tested negative for ASCL1 expression by IHC [39]. In contrast, Lewis et al. (2010) found that MCCs arising in the head and neck region were positive for ASCL1 expression [40]. Interestingly, the anti-ASCL antibody in this study and the two previous reports derived from the same antibody clone. Moreover, we show that ASCL1 expression is also absent in all tested MCC cell lines, irrespective of the MCPyV-status (Figure 2).

To the best of our knowledge we report for the first time that NeuroD1 is expressed to 100% in MCC tissues and cell lines irrespective of the MCPyV-status (Table 1, Figure 2). Interestingly, the acute B-cell lymphoblastic leukemia cell line REH also reveals a strong expression of NeuroD1, suggesting that NeuroD1 expression alone is not sufficient to induce neuroendocrine differentiation. This is supported by the fact that MCC13, MCC26 and REH were negative for the neuroendocrine genes chromogranin A and synaptophysin.

According to previous data, chromogranin A and synaptophysin gene expression is negatively regulated by REST [18,41]. Therefore, we tested the expression of REST in MCC tissues and MCC cell lines (Table 1, Figure 2). None of the MCC in our study did reveal any REST expression in the MCC cells irrespective of the MCPyV-status.

The expression of REST-GFP in the MCPyV-positive MCC cell line WaGa and the subsequent REST induced decrease of synaptophysin and chromogranin A expression reveals that chromogranin A and synaptophysin are regulated by REST also in MCC cells (Figure 4) [18,41]. Since MCC are devoid of neuroendocrine gene
activator ASCL1 expression in combination with the lack of the neuroendocrine gene repressor REST expression strongly indicates that the neuroendocrine gene expression of synaptophysin and chromogranin A in MCC is mediated by the absence of REST. NeuroD1 expression in MCC alone apparently seems to be insufficient to induce the neuroendocrine gene expression of synaptophysin and chromogranin A in the MCPyV-negative MCC (Figure 3, C and D). According to previous reports one might speculate that the high NeuroD1 expression in MCC might be responsible for the known expression of NCAM1 (CD56) in MCCs [37,42].

It is important to note, that the MCPyV-negative variant MCC cell lines MCC13 and MCC26 are currently controversially discussed in as much these cells lines indeed derive from MCC [43]. Further the absence of the neuroendocrine marker chromogranin A and synaptophysin can be explained by the expression of REST in these cells. In the context of the unknown cellular origin of MCC, it would be interesting to get more knowledge about the regulation of REST in MCC.

In this context we also assessed the methylation status of relevant REST promoter CpG islands. It has been shown previously in SCLC cells that REST expression is regulated by the CpG island methylation of the REST promoter. CpG1 and CpG3 islands were stronger methylated in SCLC REST-low expressing cell lines [32] (Figure 5). In our study, we did not observe methylation of CpG1 and CpG3 islands of the REST promoter in MCPyV-positive and -negative MCC cell lines. Moreover, the 5-aza-2′-dC treatment of the REST negative cell lines did not lead to REST expression which confirms the MSPs. Thus, the loss of REST expression in MCC is most likely not due to REST promoter methylation.

Notably, MCPyV-positive WaGa cells revealed an up to 10-fold higher expression of chromogranin A compared to the other MCPyV-positive MCC cell lines which was paralleled by also a 3-fold higher abundance of MCPyV T antigens. This might possibly hint to a direct or indirect activation of MCPyV T antigens on chromogranin A expression.

REST is not only negatively regulating the gene expression of chromogranin A and synaptophysin but also the expression of miR-9. Indeed, we could show that miR-9 and miR-9* are abundantly present in REST-negative MCPyV-positive MCC cell lines. Recently, miR-9 was found to be upregulated in 20 MCC tissues compared to cutaneous lesions of melanoma, squamous cell carcinoma, and basal cell carcinoma [25]. In cervical carcinoma and oropharyngeal squamous cell carcinoma it was shown that miR-9 is activated by HPV [26,44]. It is tempting to speculate that a comparable mechanism might be applicable to MCPyV and miR-9 expression in MCC. In the context of the unknown cellular origin of MCC the expression of miR-9 and the absence of REST might be the first step towards understanding the regulation of neuroendocrine gene expression in MCC and might help to identify the cellular ancestry of MCC [13,14].

Conclusion
MCCs reveal a unique expression pattern of the neuroendocrine key regulator genes REST, ASCL1 and NeuroD1, which is characterized by the lack of REST and ASCL1 expression and the presence of NeuroD1. The absence of REST expression in MCC and in MCPyV-positive MCC cell lines, in combination with REST expression in MCPyV-negative cell lines points to an important role of the MCPyV in the regulation of REST expression in MCC. Our data might provide the basis of MCPyV-related neuroendocrine gene expression in MCC.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.neo.2018.10.003.

Acknowledgments
We would like to thank Dr. Christopher Buck (NIH Bethesda, Washington D.C.) for calling our attention to REST and for his inspiring discussions. We thank Dr. Judith Sluimer, (MUMC+, Department of Pathology) for the helpful discussions and support. We thank Mat Rousch (MUMC+, GROW-School for Oncology & Developmental Biology, Department of Pathology) for his assistance in the experimental set up.

References
[1] Calder KB and Smoller BR (2010). New insights into Merkel cell carcinoma. Adv Anat Pathol 17(3), 155–161.
[2] Albores-Saavedra J, Batich K, Chable-Montero F, Sagg N, Schwartz AM, and Henson DE (2010). Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 37, 20–27.
[3] Hughes MP, Hardee ME, Cornelius IA, Hutchins LF, Becker JC, and Gao L (2014). Merkel Cell Carcinoma: Epidemiology, Target, and Therapy. Curr Dermatol Ret 3, 46–53.
[4] Feng H, Shuda M, Chang Y, and Moore PS (2008). Clonal Integration of a Polymavirus in Human Merkel Cell Carcinoma. Science 319, 1096–1100.
[5] Kassem A, Schopfijn A, Diaz C, Weyers W, Stickeler E, Werner M, and Zur Hausen A (2008). Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res 68, 5009–5013.
[6] Becker JC, Houben R, Ugurel S, Ttreef F, Plüibler C, and Schrama D (2009). MC polysomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol 129, 248–250.
[7] Houben R, Shuda M, Weinmann R, Schrama D, Feng H, Chang Y, Moore PS, and Becker JC (2010). Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 84, 7064–7072.
[8] Schadendorf D, Lebcb C, zur Hausen A, Avril M-F, Harirahan S, Bharmal M, and Becker JC (2017). Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 71, 53–69.
[9] Nghiem PT, Bhatia S, Lipson EF, Kudchakdar RR, Miller NJ, Annan Y, Berry S, Chartist PK, Daua A, and Fling SP, et al (2016). PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374, 2542–2552.
[10] Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo S, Bharmal M, and Becker JC (2017). Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 71, 53–69.
[11] Jankowski M, Kopinski P, Schwartz R, and Czajkowski R (2014). Merkel cell carcinoma: is this a true carcinoma? Exp Dermatol 23, 792–794.
[12] zur Hausen A, Rennspiess D, Winpenningen V, Speel E-J, and Kurz AK (2013). Early B-cell differentiation in Merkel cell carcinomas: clues to cellular ancestry. Cancer Res 73, 4982–4987.
[13] Sauer CM, Haugg AM, Chteinberg E, Rennspiess D, Winnepenninckx V, Speel E-J, Becker JC, Kurz AK, and Zur Hausen A (2017). Reviewing the current advances from REST. Crit Rev Oncol Hematol 116, 99–105.
[14] Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, Altshuller YM, Frohman MA, Kramer SD, and Mandel G (1995). REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 80(6), 949–957.
[15] Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, Leng Y, Maehs R, Shi Y, and Harper JW, et al (2008). SCF(ITRCP) controls oncogenic transformation and neural differentiation through REST degradation. Nature 452, 370–374.
[16] Ooi L and Wood IC (2007). Chromatin crosstalk in development and disease: lessons from REST. Nat Rev Genet 8, 544–554.
[17] Lietz M, Hoh M, and Thiel G (2003). RE-1 silencing transcription factor (REST) regulates human synaptophysin gene transcription through an intronic sequence-specific DNA-binding site. Eur J Biochem 270, 2–9.
Kashiwagi K, Ishii J, Sakaeda M, Arimasu Y, Shimoyamada H, Sato H, Miyata C, Kamma H, Aoki I, and Yazawa T (2012). Differences of molecular expression mechanisms among neural cell adhesion molecule 1, synaptophysin, and chromogranin A in lung cancer cells. *Pathol Int* 62, 232–245.

Conti L, Crisafulli L, Caldera V, Tortoreto M, Brilli E, Conforti P, Zunino F, Magrassi L, Schiffer D, and Cartanese E (2012). REST controls self-renewal and tumorigenic competence of human glioblastoma cells. *PLoS One* 7:e38486.

Fuller GN, Su X, Price RE, Cohen ZR, Lang FF, Sawaya R, and Majumder S (2012). Comprehensive analysis of CpG islands in human chromosomes 21 and 22. *Proc Natl Acad Sci U S A* 99, 3740–3745.

Chteinberg et al. (2018). Neuroendocrine Key Regulator Genes in Merkel Cell Carcinoma. *Neoplasia* Vol. 20, No. 12, 2018.

Oncogene 29, 5828–5838.

Takai D and Jones PA (2002). Comprehensive analysis of CpG islands in human chromosomes 21 and 22. *Proc Natl Acad Sci U S A* 99, 3740–3745.

Coulson JM, Edgson JL, Woll PJ, and Quinn JP (2000). A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. *Cancer Res* 60, 1840–1844.

Chen G-L and Miller GM (2013). Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer. *PLoS One* 8:e62217.

Borromero Mark D, Savage Trisha K, Kollipara Rahul K, He M, Augustyn A, Osborne Jihan K, Girard L, Minna John D, Gazdar Adi F, and Cobb Melanie H, et al (2016). ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. *Cell Rep* 16, 1259–1272.

Yazawa T (2015). Recent advances in histogenesis research of lung neuroendocrine cancers: Evidence obtained from functional analyses of primary neural/neuroendocrine cell-specific transcription factors. *Pathol Int* 65, 277–285.

Osborne JK, Larsen JE, Shields MD, Gonzales JX, Shames DS, Sato M, Kulkarni A, Wistuba II, Girard L, and Minna JD, et al (2013). NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. *PLoS One* 8:e62217.

Ralston J, Chiriboga L, and Nonaka D (2008). MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma. *Mod Pathol* 21, 1357–1362.

Lewis Jr JS, Duncavage E, and Klowski PW (2010). Oral cavity neuroendocrine carcinoma: a comparison study with cutaneous Merkel cell carcinoma and other mucosal head and neck neuroendocrine carcinomas. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 110, 209–217.

Wagoner MP, Gunsalus KTW, Schoenike B, Richardson AL, Friedl A, and Roopra A (2010). The transcription factor REST is lost in aggressive breast cancer. *PLoS Genet* 6:e1000979.

Osborne JK, Larsen JE, Gonzales JX, Shames DS, Sato M, Wistuba II, Girard L, Minna JD, and Cobb MH (2013). NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition. *Oncogene* 285.

Kassem A, Schöpflin A, Diaz C, Weyers W, Stickeler E, Werner M, and zur Hausen A (2008). Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the chromosomal region 7q11-q21 in Merkel cell carcinoma tissues. *Oncogene* 285.

Gao G, Gay HA, Chernock RD, Zhang TR, Luo J, Thorstad WL, Lewis JS, and Wang X (2013). A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. *Cancer* 119, 72–80.